NCT00322608已完成1 期
Phase I Study of the Vascular Disrupting Agent NPI-2358 Administered Via Intravenous Infusion in Patients With Advanced Solid Tumor Malignancies or Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 35
- 试验地点
- 3
- 主要终点
- Safety
研究概览
简要总结
This is a Phase 1 clinical trial examining the safety, pharmacokinetics and pharmacodynamics of escalating doses of the vascular disrupting agent NPI-2358 in patients with refractory solid tumors or lymphoma. The formation of new blood vessels (angiogenesis) is an important component of tumor growth and vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues. NPI-2358 has also been seen to directly affect tumor cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ECOG performance status ≤ 2
- •Pathologically or histologically confirmed solid tumor malignancy
- •Patients must not be candidates for regimens known to provide clinical benefit.
- •All adverse events of any prior chemotherapy, surgery, or radiotherapy, must have resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (v. 3.0) Grade ≤ 2, except for neurological toxicity that must have resolved to Grade ≤
- •Adequate bone marrow reserve, hepatic and renal function
- •Signed informed consent
排除标准
- •Administration of chemotherapy, biological, immunotherapy or investigational agent (therapeutic or diagnostic) within 21 days prior to receipt of study medication (6 weeks for nitrosoureas or mitomycin C; 12 weeks for radioimmunotherapy). Major surgery, other than diagnostic surgery, within 6 weeks before first study drug administration. Radiotherapy within 4 weeks (some types of radiation therapy are excluded regardless of interval since treatment).
- •Significant cardiac history or findings
- •Underlying conditions or medications associated with bleeding diathesis
- •Disorders associated with significant vascular pathology
- •Lung cancer with central chest tumors
- •Prior treatment with vascular disruptive agents
- •Seizure disorder requiring anticonvulsant therapy; prior transient ischemic attack or cerebrovascular accident
- •Brain metastases
- •Severe chronic obstructive pulmonary disease (COPD) with hypoxemia
- •Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy
- •Known infection with human immunodeficiency virus (HIV), active hepatitis A, B, or C
- •Patients with a prior hypersensitivity reaction to any product containing Solutol and/or propylene glycol
- •Pregnant or breast-feeding women. Female patients must be postmenopausal, surgically sterile or they must agree to use acceptable methods of birth control. Female patients with childbearing potential must have a negative serum pregnancy test. Male patients must be surgically sterile or agree to use an acceptable method of contraception.
- •Concurrent, active second malignancy for which the patient is receiving therapy, excluding basal cell carcinoma of the skin or carcinoma in situ of the cervix
研究组 & 干预措施
Dose escalation
Experimental
干预措施: NPI-2358 (Drug)
结局指标
主要结局
Safety
时间窗: continuously
Tolerability
时间窗: continuously
Maximum tolerated dose (MTD)
时间窗: continuously
次要结局
- Pharmacokinetics(continuously)
- Pharmacodynamics(continuously)
- Response Evaluation Criteria in Solid Tumors (RECIST)(continuously)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced MalignanciesAdvanced CancerNCT00629473Celgene86
已完成
1 期
Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid MalignancySolid TumorMetastatic CancerNCT02412462Alethia Biotherapeutics15
终止
1 期
VNRX-9945 Safety and Pharmacokinetics in Healthy Adult VolunteersHealthy VolunteersNCT04845321Venatorx Pharmaceuticals, Inc.32
已完成
1 期
A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2HealthyNCT04384081Boehringer Ingelheim37
尚未招募
1 期
F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus ErythematosusLupus ErythematosisNCT06468683Shanghai Simnova Biotechnology Co.,Ltd.50